ReoPro (Centocor) en es it fr

ReoPro (Centocor) Brand names, ReoPro (Centocor) Analogs

ReoPro (Centocor) Brand Names Mixture

  • No information avaliable

ReoPro (Centocor) Chemical_Formula


ReoPro (Centocor) RX_link

ReoPro (Centocor) fda sheet

ReoPro_(Centocor) FDA

ReoPro (Centocor) msds (material safety sheet)

ReoPro (Centocor) Synthesis Reference

(sequence listed in Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.Arterioscler Thromb. 1993 Dec;13(12):1837-42.) patent EP418316

ReoPro (Centocor) Molecular Weight


ReoPro (Centocor) Melting Point

61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

ReoPro (Centocor) H2O Solubility

No information avaliable

ReoPro (Centocor) State


ReoPro (Centocor) LogP


ReoPro (Centocor) Dosage Forms

Solution (IV Infusion)

ReoPro (Centocor) Indication

For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina

ReoPro (Centocor) Pharmacology

Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.

ReoPro (Centocor) Absorption

No information avaliable

ReoPro (Centocor) side effects and Toxicity

No information avaliable

ReoPro (Centocor) Patient Information

No information avaliable

ReoPro (Centocor) Organisms Affected

Humans and other mammals